Skip to content

Effect of early plasmapheresis and routine therapy on organ function in hypertriglyceridemic acute pancreatitis

Effect of early plasmapheresis and routine therapy on organ function in hypertriglyceridemic acute pancreatitis

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100049081
Enrollment
Unknown
Registered
2021-07-20
Start date
2021-08-01
Completion date
Unknown
Last updated
2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute pancreatitis with hypertriglyceridemia

Interventions

Plasma exchange group:plasma exchange
Conventional treatment group:Conventional treatment group

Sponsors

Beijing Luhe Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Adults (18-70 years old); 2. Within 48 hours of onset, the diagnosis of HTG-AP is clear; 3. TG>1000mg/dL (11.3mmol/L) at the time of enrollment, and accompanied by any one or more of the following clinical manifestations: (1) Lactic acid>2mmol/L and pH38.5? or 90 beats/min; 3) Breathing>20 times/min or PaCO2>32mmHg; 4) WBC count>12000/ml or 10%; (4) Organ failure was assessed by modified Marshall score.

Exclusion criteria

Exclusion criteria: 1. AP caused by other causes other than hyperlipidemia, such as gallstones, alcohol, etc 2. Patients with uncorrected acidosis (pH =6.5mmol/L) requiring emergency CRRT at the time of randomization; 3. Contraindication to plasma exchange: severe allergic history to plasma, human serum albumin, heparin, etc.;There are mental disorders and can not cooperate well with treatment;Systemic circulatory failure that is difficult to correct with drugs;Unstable heart and cerebral infarction;Intracranial hemorrhage or severe cerebral edema accompanied by cerebral hernia; 4. Patients refuse plasmapheresis without informed consent, and other conditions that may bring significant bias; 5. Pregnant and lactating women;Or subjects (including male subjects) who plan to become pregnant within 1 month after the trial; 6. Sponsors or researchers directly involved in the trial or their family members; 7. The investigator determined that there was any reason for the ineligibility, such as the expectation that the patient would die within 48 hours of enrolment.

Design outcomes

Primary

MeasureTime frame
triglyceride;hemodiastase;

Countries

China

Contacts

Public ContactWeng Yibing

Beijing Luhe Hospital

wangguan@ccmu.edu.cn+86 8610 69543901 2128

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026